Table 4.
The 1-Year Clinical Outcomes According to Post-LAAO Medications (Mutually Exclusive Categories)
| OAC | APT | APT (n = 1,176; 38.1%) |
OAC | OAC | APT (n = 832; 27.0%) | OAC + APT | APT | APT (n = 202; 6.6%) | OAC | OAC | OAC (n = 348; 11.3%) | APT | APT | APT (n = 150; 4.9%) | Others (n = 374; 12.1%) | ||||
|---|---|---|---|---|---|---|---|---|---|
| OAC | DAPT | DAPT (n = 191; 6.2%) | OAC | SAPT | SAPT (n = 352; 11.4%) | OAC | DAPT | SAPT (n = 633; 20.5%) | Total | ||||||
| CHA2DS2-VASc score | 3.73 ± 1.81 | 3.76 ± 1.80 | 3.87 ± 1.75 | 3.81 ± 1.78 | 3.92 ± 1.77 | 4.16 ± 1.94 | 4.27 ± 1.82 | 4.29 ± 1.80 | 4.07 ± 1.81 |
| HAS-BLED score | 2.24 ± 1.18 | 2.26 ± 1.12 | 2.27 ± 1.14 | 2.26 ± 1.14 | 2.31 ± 1.13 | 2.56 ± 1.28 | 2.51 ± 1.11 | 2.82 ± 1.19 | 2.67 ± 1.14 |
| ATRIA score | 5.73 ± 3.01 | 5.98 ± 2.98 | 6.04 ± 3.03 | 5.97 ± 3.01 | 6.24 ± 2.97 | 6.10 ± 2.90 | 6.72 ± 2.82 | 7.02 ± 2.69 | 6.23 ± 2.85 |
| Total | |||||||||
| Death, stroke, systemic embolism | 6/191 (3.2) | 13/352 (3.9) | 14/633 (2.3) | 33/1,176 (2.9) | 23/832 (3.0) | 6/202 (3.0) | 35/348 (10.8) | 12/150 (8.3) | 24/374 (6.6) |
| Life-threatening, disabling, or major bleeding | 2/191 (1.0) | 7/352 (2.0) | 5/633 (0.8) | 14/1,176 (1.2) | 20/832 (2.5) | 5/202 (2.5) | 12/348 (3.8) | 8/150 (5.4) | 12/374 (3.3) |
| Death; stroke; systemic embolism; and any life-threatening, disabling, or major bleeding | 7/191 (3.7) | 16/352 (4.8) | 17/633 (2.7) | 40/1,176 (3.5) | 40/832 (5.0) | 9/202 (4.5) | 39/348 (12.0) | 18/150 (12.3) | 31/374 (8.5) |
| HAS-BLED score <3 | |||||||||
| Death, stroke, systemic embolism | 3/119 (2.6) | 6/208 (2.9) | 3/377 (0.8) | 12/704 (1.7) | 8/481 (1.8) | 3/97 (3.1) | 12/181 (7.2) | 0/60 (0.0) | 5/168 (3.2) |
| Life-threatening, disabling, or major bleeding | 1/119 (0.8) | 4/208 (1.9) | 4/377 (1.1) | 9/704 (1.3) | 11/481 (2.4 | 0/97 (0.0) | 3/181 (1.7) | 4/60 (6.7) | 3/168 (1.8) |
| Death; stroke; systemic embolism; and any life-threatening, disabling, or major bleeding | 4/119 (3.4) | 7/208 (3.4) | 6/377 (1.6) | 17/704 (2.4) | 18/481 (3.9) | 3/97 (3.1) | 13/181 (7.7) | 4/60 (6.7) | 8/168 (5.0) |
| HAS-BLED score ≥3 | |||||||||
| Death, stroke, systemic embolism | 3/72 (4.3) | 7/144 (5.3) | 11/256 (4.4) | 21/472 (4.7) | 15/351 (4.5) | 3/105 (2.9) | 23/167 (14.8) | 12/90 (13.7) | 19/206 (9.4) |
| Life-threatening, disabling, or major bleeding | 1/72 (1.4) | 3/144 (2.1) | 1/256 (0.4) | 5/472 (1.1) | 9/351 (2.6) | 5/105 (4.8) | 9/167 (6.0) | 4/90 (4.6) | 9/206 (4.5) |
| Death; stroke; systemic embolism; and any life-threatening, disabling, or major bleeding | 3/72 (4.2) | 9/144 (6.6) | 11/256 (4.4) | 23/472 (5.1) | 22/351 (6.5) | 6/105 (5.8) | 26/167 (16.6) | 14/90 (16.0) | 23/206 (11.3) |
Values are mean ± SD or n/N (%).
APT = antiplatelet therapy; DAPT = dual-antiplatelet therapy; LAAO = left atrial appendage occlusion; OAC = oral anticoagulant; SAPT = single-antiplatelet therapy.